BLBin Lv

Bin Lv

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bin Lv has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Yuqi Zhang

    Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China

    3 shared publications
  • Tianyi Cui

    Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China

    2 shared publications
  • Xiaoying Wang

    School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China

    2 shared publications
  • Xin Zhao

    Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China

    2 shared publications
  • Xiumei Gao

    Ministry of Education Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, Jinghai, Tianjin 301617, China

    2 shared publications
  • Yang Chen

    Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China

    2 shared publications

Latest Publications

  • Open Access

    Research progress on lysine acetylation (Review)

    by Minghui Zhang, Yuqi Zhang, Haoxin Yin, Junyuan Yan, Yingling Dong, Xin Zhao, Tianyi Cui, Bin Lv, Xiumei Gao

    Lysine acetylation is recognized as a critical and reversible post‑translational modification that is essential for numerous cellular functions and biological processes. The dynamic interplay between lysine acetylation and deacetylation to regulates a wide spectrum of processes, including histone modification, gene expression, cell cycle progression, DNA repair and signal transduction. Emerging evidence has demonstrated that the dysregulation of lysine acetylation is strongly associated with multiple diseases, including cancer, cardiovascular diseases, chronic inflammatory diseases and neurological diseases. These alterations can modify gene expression and disrupt cellular homeostasis. The present review aimed to highlight the biological functions of lysine acetyltransferases and lysine deacetylases, their contributions to disease pathogenesis, and the interplay the crosstalk of lysine acetylation with other post‑translational modifications. Drawing on the latest research findings, the therapeutic potential of targeting acetylation pathways is discussed, with the aim of providing new insight into the development of innovative treatment strategies and clinical applications.

  • Top Cited Papers
    Open Access

    Synergistic anti-oxidative/anti-inflammatory treatment for acute lung injury with selenium based chlorogenic acid nanoparticles through modulating Mapk8ip1/MAPK and Itga2b/PI3k-AKT axis

    by Huizhen Xing, Xinwei Bai, Xiaoying Pei, Yuqi Zhang, Xueying Zhang, Shujun Chen, Dan Li, Bin Lv, Xiaoying Wang, Xiaoli Wu

    Oxidative stress and inflammatory dysregulation play crucial roles in pathogenesis of acute lung injury (ALI), and their cyclic synergy drives excessive inflammatory responses and further exacerbates ALI. Therefore, new effective strategies to treat ALI are urgently needed. Herein, a novel synergistic selenium based chlorogenic acid nanoparticle was developed to disrupt the cyclic synergistic effect between oxidative stress and inflammatory response in ALI. The chlorogenic acid, a polyphenol commonly found in herb, had been effectively conjugated with human serum albumin and coated on selenium nanoparticles (Se NPs) to create CHSe NPs. The CHSe NPs exhibited superoxide dismutase(SOD) like and glutathione peroxidase(GPX) like activities, effectively scavenging various types of reactive oxygen species (ROS), and inhibited the inflammatory response of macrophages. Additionally, with excellent biosafety, CHSe NPs exhibited superior therapeutic effects in ALI mice models in vivo, surpassing the performance of the clinic drug dexamethasone. They remarkably reduced ROS levels, and elevated the SOD and GPX enzyme activities in lung tissue to exert antioxidant effects. In addition, the CHSe NPs modulated the immune microenvironment of ALI by reversing M1 macrophage polarization, downregulating the expression levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-a), nitric oxide synthase (iNOS), and myeloperoxidase (MPO), and upregulating anti-inflammatory cytokine (IL-10) levels, thereby alleviating excessive inflammation and decreasing neutrophil infiltration. Further mechanistic research revealed that CHSe NPs directly acted on and modulated the expression of Mapk8ip1 and Itga2b, which were upstream proteins of MAPK signaling pathway and PI3K-Akt signaling pathway, therefore impeding the cyclic synergy between oxidative stress and inflammatory dysregulation. In summary, CHSe NPs synergistically exert antioxidant and anti-inflammatory effects by regulating the MAPK signaling pathway and PI3K-Akt signaling pathway, showing enormous potential in the treatment of ALI.


  • Perilla frutescens leaf extracts alleviate acute lung injury in mice by inhibiting KAT2A

    by Jinhe Guo, Yuqi Zhang, Yaodong Du, Yang Chen, Xin Zhao, Bin Yu, Tianyi Cui, Haoping Mao, Bin Lv, Xiaoying Wang, et al.


  • Open Access

    KAT2A-targeted inhibition prevents an inflammatory response to protect the myocardium

    by Bin Lv, Xiaoying Wang, Haiyang Yu, Yang Chen, Jinhe Guo, Yaodong Du, Chao Feng, Rutao Cui, Xiumei Gao

    Background: Hyperactive inflammation is crucial for the development of acute myocardial infarction (AMI) to heart failure and can promote impaired cardiac function, and it is difficult to determine its specific therapeutic targets and drugs. Therefore, it is necessary to develop new therapeutic strategies to control inflammatory responses to protect myocardial cells during AMI. Methods: Levels of critical cardiac markers and inflammatory factors were measured in blood samples collected from clinical patients with AMI to analyze the association between the serum expression levels of inflammatory factors and the progression of AMI. To uncover the mechanism underlying the association between inflammatory response and AMI, microarray analysis was performed to identify key myocardial cell regulators. ATAC-seq was also performed to identify how immune response genes are transcriptionally regulated by KAT2A. KAT2A-/- genetically engineered mice were used to validate the screened targets. Finally, a small molecule targeting KAT2A was developed and tested in a rat model of AMI. Results: Here we show that KAT2A, a histone H3K9 acetyltransferase, is a key factor regulating the inflammatory response in AMI. Specifically, the level of cardiac damage was initially found to be associated with the inflammatory response in patients with AMI. Regarding the mechanism, KAT2A transcriptionally regulates pro-inflammatory tumor necrosis factor alpha and interleukin-6 to induced cardiomyocyte damage. Using a genetically engineered mouse model of AMI, we show that targeted KAT2A loss or inhibition prevents the recruitment of immune cells into the myocardium to suppress the inflammatory explosion in AMI in vivo and significantly improved heart function. Finally, Tanshinone I, a KAT2A-targeted inhibitor, could inhibited the inflammatory response in AMI in vivo. Conclusion: KAT2A is a potential therapeutic target for AMI, especially for inhibiting the inflammatory response to this condition. As a specific KAT2A-targeted inhibitor, Tanshinone I is a potent candidate drug for AMI.